Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cidofovir plus radiotherapy in HPV-positive oropharyngeal cancer
NL-OMON27994Phase 1Active, not recruiting
- Sponsor
- Maastricht University Medical Center+
- Start
- Jul 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cidofovir in oropharyngeal cancer and head and neck squamous cell carcinoma (HNSCC), sponsored by Maastricht University Medical Center+. Primary endpoint: Maximum tolerated dose of cidofovir. Started Jul 2008; status: active, not recruiting.
02
Drugs
cidofovir
03
Conditions
oropharyngeal cancerhead and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NL-OMON27994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON27994.